CymitQuimica logo

CAS 1193383-09-3

:

Sort by

Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
  • 1H-Pyrazole-4-carboxylic acid, 1-[6-chloro-5-(trifluoromethoxy)-1H-benzimidazol-2-yl]-

    CAS:
    Formula:C12H6ClF3N4O3
    Purity:%
    Color and Shape:Solid
    Molecular weight:346.6492

    Ref: IN-DA000IM5

    1mg
    63.00€
    5mg
    64.00€
    50mg
    222.00€
    100mg
    502.00€
    250mg
    To inquire
  • 1-(6-Chloro-5-(Trifluoromethoxy)-1H-Benzo[D]Imidazol-2-Yl)-1H-Pyrazole-4-Carboxylic Acid

    CAS:
    1-(6-Chloro-5-(Trifluoromethoxy)-1H-Benzo[D]Imidazol-2-Yl)-1H-Pyrazole-4-Carboxylic Acid
    Purity:98%
    Molecular weight:346.65g/mol

    Ref: 54-PC108738

    1g
    1,556.00€
    100mg
    359.00€
    250mg
    599.00€
  • JNJ-42041935

    CAS:
    <p>JNJ-42041935</p>
    Purity:≥95%
    Molecular weight:346.65g/mol

    Ref: 54-BUP08199

    2mg
    76.00€
    5mg
    122.00€
    10mg
    185.00€
    25mg
    306.00€
    50mg
    504.00€
    100mg
    780.00€
  • JNJ-42041935

    CAS:
    <p>JNJ-42041935 (HIF-PHD Inhibitor II) is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.</p>
    Formula:C12H6ClF3N4O3
    Purity:99.58% - ≥95%
    Color and Shape:Solid
    Molecular weight:346.65
  • JNJ 42041935

    Controlled Product
    CAS:
    <p>Applications JNJ 42041935 is a selective hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) enzyme inhibitor. It can potentially be used for the treatment of inflammation-induced anemia.<br>References Barrett, T., et al.: Mol. Pharmacol., 79, 910 (2011); Thirstrup, K., et al.: Pharmacol. Res., 64, 268 (2011);<br></p>
    Formula:C12H6ClF3N4O3
    Color and Shape:Neat
    Molecular weight:346.65

    Ref: TR-J211318

    1mg
    107.00€
    5mg
    238.00€
    10mg
    370.00€
  • JNJ 42041935

    CAS:
    <p>JNJ 42041935 is a pharmacologic agent that inhibits the growth of cancer cells and may be used to treat chronic kidney disease. This drug binds to the extracellular matrix, which prevents the proliferation of cells in the tissue. JNJ 42041935 has been shown to inhibit the production of messenger RNA in urine samples taken from patients with chronic kidney disease. The clinical studies have shown that JNJ 42041935 can reduce the incidence of leukemia and blood disorders. The effective dose for this drug is not yet known, but it is thought that it may be around 1-10 mg/kg daily. It is also unknown how long JNJ 42041935 will remain in the body or what its excretion rate is.</p>
    Formula:C12H6ClF3N4O3
    Purity:Min. 95%
    Molecular weight:346.65 g/mol

    Ref: 3D-TXB38309

    25mg
    1,102.00€
    50mg
    1,533.00€
    100mg
    2,389.00€